RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis

作者：Mathias Dahlmann, Anna Okhrimenko, Patrick Marcinkowski, Marc Osterland, Pia Herrmann, Janice L. Smith, Claus W. Heizmann, Peter Michael Schlag, Ulrike Stein · 发表于：Oncotarget · 年份：2014 · DOI：10.18632/oncotarget.1908 · 被引用次数：120 · 研究领域：S100 Proteins and Annexins、Advanced Glycation End Products research、Neonatal Respiratory Health Research

// Mathias Dahlmann 1 , Anna Okhrimenko 1 , Patrick Marcinkowski 1 , Marc Osterland 1 , Pia Herrmann 1 , Janice Smith 2 , Claus W. Heizmann 3 , Peter M. Schlag 1,4 , Ulrike Stein 1 1 Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany 2 Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany 3 University Children’s Hospital, Division of Clinical Chemistry and Biochemistry, Steinwiesstrasse 75, 8032 Zürich, Switzerland 4 Charité Comprehensive Cancer Center, Charité University Medicine, Invalidenstraße 80, 10117 Berlin, Germany Correspondence: Ulrike Stein, email: // Keywords : Colorectal cancer, metastasis, S100A4, RAGE, signaling Received : February 03, 2014 Accepted : April 16, 2014 Published : April 17, 2014 Abstract Survival of colorectal cancer patients is strongly dependent on development of distant metastases. S100A4 is a prognostic biomarker and inducer for colorectal cancer metastasis. Besides exerting intracellular functions, S100A4 is secreted extracellularly. The receptor for advanced glycation end products (RAGE) is one of its interaction partners. The impact of the S100A4-RAGE interaction for cell motility and metastasis formation in colorectal cancer has not been elucidated so far. Here we demonstrate the RAGE-dependent increase in migratory and invasive capabilities of colorectal cancer cells via binding to ...